Accelerating Life- Changing Medicines

We are knowledgeable, confident and results-oriented experts who work with a sense of urgency to identify, acquire and accelerate development and delivery of transformative medicines for patients.

Recent News

ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio...

The acquisition of ValenzaBio adds multiple clinical and pre-clinical development programs to ACELYRIN’s robust immunology pipeline, which is led by izokibep....

Icon 1 / 3 Icon
Acelyrin Test Tube Icon

Our Science

We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care.

Learn More
Acelyrin Team Icon

Meet Our Leadership

We are led by experienced biopharma executives with exceptional track records of building strong companies, delivering innovative treatments and growing diverse teams.

Learn More

Courageous Caring

Guided by our key cultural value of Courageous Caring, and driven by a sense of urgency, we are building an innovative biopharma company that aims to invest in, develop and commercialize clinically meaningful therapies.


Patients dosed with izokibep


Dedicated professionals

$ M+

Growth financing committed

Clinical-stage programs

We Care as Scientists, and We Care as People
Who We Are

We Care as Scientists, and We Care as People

We have the right blend of scientific, medical, operational and corporate experience to identify, develop and commercialize treatments with the potential to dramatically transform patients’ lives.
Our Story Arrow purple
Our Work

Accelerating Transformative Therapies

We are actively investigating the potential of izokibep and other programs in diseases where differentiated therapeutic approaches are required to address unmet patient needs.

Shao-Lee Lin, MD, PhD
“We are leveraging the power of our team to build a better and brighter future for patients in need.”
Shao-Lee Lin, MD, PhD | Founder and Chief Executive Officer

Join a team that Courageously Cares

ACELYRIN is building a biopharma company with a corporate culture of Courageous Caring - placing patients first and embracing the concept that all of us together are better than any one of us alone. We strive to address the most basic human needs: to live a productive life free from disease.
Learn More Arrow purple
Join a team that Courageously Cares

In the Press


Immunology-Drug Startup Acelyrin Raises $300 Million for Late-Stage Trials

Immune-focused drugmaker has raised more than $550 million in venture capital.

Read Article Arrow purple

Acelyrin scores series C that brings total raised in less than a year past $500M

Any biotech that can rake in half a billion dollars from investors in 12 months is clearly doing something right.

Read Article Arrow purple

Izokibep Treatment Improves Pain, Function in Patients with Active PsA

Unique IL-17A inhibitor demonstrated notable dose-dependent improvements in sleep, pain and function in patients with psoriatic arthritis.

Read Article Arrow purple
News Center

The Latest Company
Announcements and Resources